


**Amendments to the claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (original). A compound of formula (I):



(I)

wherein

A is a fused 5-membered heteroaryl ring optionally substituted by up to two substituents independently selected from C<sub>1-6</sub>alkyl, -(CH<sub>2</sub>)<sub>m</sub>-C<sub>3-7</sub>cycloalkyl, halogen, cyano, trifluoromethyl, -(CH<sub>2</sub>)<sub>m</sub>OR<sup>3</sup>, -(CH<sub>2</sub>)<sub>m</sub>CO<sub>2</sub>R<sup>3</sup>, -(CH<sub>2</sub>)<sub>m</sub>NR<sup>3</sup>R<sup>4</sup>, -(CH<sub>2</sub>)<sub>m</sub>CONR<sup>3</sup>R<sup>4</sup>, -(CH<sub>2</sub>)<sub>m</sub>NHCOR<sup>3</sup>, -(CH<sub>2</sub>)<sub>m</sub>SO<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>, -(CH<sub>2</sub>)<sub>m</sub>NHSO<sub>2</sub>R<sup>3</sup>, -(CH<sub>2</sub>)<sub>m</sub>SO<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>R<sup>5</sup>, a 5- or 6-membered heterocyclyl ring containing nitrogen optionally substituted by C<sub>1-2</sub>alkyl or -(CH<sub>2</sub>)<sub>m</sub>CO<sub>2</sub>R<sup>3</sup>, and a 5-membered heteroaryl ring optionally substituted by C<sub>1-2</sub>alkyl;

R<sup>1</sup> is selected from methyl and chloro;

R<sup>2</sup> is selected from -NH-CO-R<sup>6</sup> and -CO-NH-(CH<sub>2</sub>)<sub>q</sub>-R<sup>7</sup>;

R<sup>3</sup> is selected from hydrogen, C<sub>1-6</sub>alkyl optionally substituted by up to two OH groups, -(CH<sub>2</sub>)<sub>m</sub>-C<sub>3-7</sub>cycloalkyl, -(CH<sub>2</sub>)<sub>m</sub>phenyl optionally substituted by R<sup>8</sup> and/or R<sup>9</sup> and -(CH<sub>2</sub>)<sub>m</sub>heteroaryl optionally substituted by R<sup>8</sup> and/or R<sup>9</sup>,

R<sup>4</sup> is selected from hydrogen and C<sub>1-6</sub>alkyl, or

R<sup>3</sup> and R<sup>4</sup>, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R<sup>10</sup>;

R<sup>5</sup> is selected from C<sub>1-6</sub>alkyl optionally substituted by up to three halogen atoms, C<sub>2-6</sub>alkenyl optionally substituted by phenyl, C<sub>3-7</sub>cycloalkyl, heteroaryl

optionally substituted by up to three R<sup>8</sup> and/or R<sup>9</sup> groups, and phenyl optionally substituted by R<sup>8</sup> and/or R<sup>9</sup>;

R<sup>6</sup> is selected from hydrogen, C<sub>1-6</sub>alkyl, -(CH<sub>2</sub>)<sub>q</sub>-C<sub>3-7</sub>cycloalkyl, trifluoromethyl, -(CH<sub>2</sub>)<sub>r</sub>heteroaryl optionally substituted by R<sup>11</sup> and/or R<sup>12</sup>, and -(CH<sub>2</sub>)<sub>r</sub>phenyl optionally substituted by R<sup>11</sup> and/or R<sup>12</sup>;

R<sup>7</sup> is selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, -CONHR<sup>13</sup>, phenyl optionally substituted by R<sup>11</sup> and/or R<sup>12</sup>, and heteroaryl optionally substituted by R<sup>11</sup> and/or R<sup>12</sup>;

R<sup>8</sup> and R<sup>9</sup> are each independently selected from halogen, cyano, trifluoromethyl, nitro, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, -CONR<sup>13</sup>R<sup>14</sup>, -COR<sup>15</sup>, -CO<sub>2</sub>R<sup>15</sup>, and heteroaryl, or

R<sup>8</sup> and R<sup>9</sup> are linked to form a fused 5-membered heterocyclyl ring containing one heteroatom selected from oxygen, sulphur and N-R<sup>10</sup>, or a fused heteroaryl ring;

R<sup>10</sup> is selected from hydrogen and methyl;

R<sup>11</sup> is selected from C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, -(CH<sub>2</sub>)<sub>q</sub>-C<sub>3-7</sub>cycloalkyl, -CONR<sup>13</sup>R<sup>14</sup>, -NHCOR<sup>14</sup>, halogen, CN, -(CH<sub>2</sub>)<sub>s</sub>NR<sup>16</sup>R<sup>17</sup>, trifluoromethyl, phenyl optionally substituted by one or more R<sup>12</sup> groups, and heteroaryl optionally substituted by one or more R<sup>12</sup> groups;

R<sup>12</sup> is selected from C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, trifluoromethyl, and -(CH<sub>2</sub>)<sub>s</sub>NR<sup>16</sup>R<sup>17</sup>;

R<sup>13</sup> and R<sup>14</sup> are each independently selected from hydrogen and C<sub>1-6</sub>alkyl, or

R<sup>13</sup> and R<sup>14</sup>, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R<sup>10</sup>, wherein the ring may be substituted by up to two C<sub>1-6</sub>alkyl groups;

R<sup>15</sup> is C<sub>1-6</sub>alkyl;

R<sup>16</sup> is selected from hydrogen, C<sub>1-6</sub>alkyl and -(CH<sub>2</sub>)<sub>q</sub>-C<sub>3-7</sub>cycloalkyl optionally substituted by C<sub>1-6</sub>alkyl,

R<sup>17</sup> is selected from hydrogen and C<sub>1-6</sub>alkyl, or

R<sup>16</sup> and R<sup>17</sup>, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R<sup>10</sup>;

X and Y are each independently selected from hydrogen, methyl and halogen;

m is selected from 0, 1, 2 and 3;

n is selected from 0, 1, 2 and 3;

q is selected from 0, 1 and 2;

r is selected from 0 and 1; and

s is selected from 0, 1, 2 and 3.

2 (original). A compound according to claim 1 wherein A is a fused 5-membered heteroaryl ring containing up to two heteroatoms independently selected from oxygen

and nitrogen optionally substituted by up to two substituents independently selected from  $C_{1-4}$ alkyl,  $-(CH_2)_m-C_{3-7}$ cycloalkyl,  $-(CH_2)_mCO_2R^3$ ,  $-(CH_2)_mNR^3R^4$ ,  $-(CH_2)_mCONR^3R^4$ ,  $-(CH_2)_mNHCOR^3$ ,  $-(CH_2)_mSO_2(CH_2)_nR^5$ , and a 5- or 6-membered heterocyclyl ring containing nitrogen optionally substituted by  $C_{1-2}$ alkyl or  $-(CH_2)_mCO_2R^3$ .

- 3 (previously presented). A compound according to claim 1 wherein  $R^1$  is methyl.
- 4 (previously presented). A compound according to claim 1 wherein  $R^2$  is  $-CO-NH-(CH_2)_q-R^7$ .
- 5 (previously presented). A compound according to claim 1 wherein X is hydrogen or fluorine.
- 6 (Currently amended). A compound according to claim 1 which is:

N-Cyclopropyl-4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)benzamide;

4-Methyl-N-(3-morpholin-4-ylphenyl)-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)benzamide;

N-[4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide;

N-[4-Methyl-3-(3-methyl-1,2-benzisoxazol-6-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide; (~~GW-847258X~~)

N-[4-Methyl-3-(3-methyl-1,2-benzisoxazol-6-yl)phenyl]thiophene-3-carboxamide;

N-[4-Methyl-3-(3-methyl-1,2-benzisoxazol-6-yl)phenyl]-3-furamide;

4-Methyl-3-(3-methyl-1,2-benzisoxazol-6-yl)-N-(3-morpholin-4-ylphenyl)benzamide;

4-Methyl-3-(3-methyl-1,2-benzisoxazol-6-yl)-N-(1,3-thiazol-2-yl)benzamide;

N-Cyclopropyl-4-methyl-3-(3-methyl-1,2-benzisoxazol-6-yl)benzamide;

N-[4-Methyl-3-(3-methyl-1,2-benzisoxazol-5-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide;

N-Cyclopropyl-3-[3-({[2-hydroxy-1-(hydroxymethyl)ethyl]amino}methyl)-1,2-benzisoxazol-6-yl]-4-methylbenzamide;

N-(3-Methoxyphenyl)-4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)benzamide;

4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)-N-(1,3,4-thiadiazol-2-yl)benzamide;

N-[4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]thiophene-3-carboxamide;

N-[4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]-3-furamide;

N-(Cyclopropylmethyl)-4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)benzamide;

N-Cyclopropyl-3-(1H-indazol-5-yl)-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-[1-(phenylsulfonyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-[1-[(3-fluorophenyl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide;

3-[1-[(3-Cyanophenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-4-methylbenzamide;

N-Cyclopropyl-3-[1-[(3,4-difluorophenyl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide;

(GW 824473X)-N-Cyclopropyl-4-methyl-3-[1-(methylsulfonyl)-1H-indazol-5-yl]benzamide-(GW 825587X)

N-Cyclopropyl-3-[1-(2,3-dihydro-1-benzofuran-5-ylsulfonyl)-1H-indazol-5-yl]-4-methylbenzamide;

N-Cyclopropyl-3-[1-[(3-methoxyphenyl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide;

3-[1-(Benzylsulfonyl)-1H-indazol-5-yl]-N-cyclopropyl-4-methylbenzamide;

N-Cyclopropyl-3-[1-[(5-isoxazol-3-ylthien-2-yl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide;

3-[1-[(4-Acetylphenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-4-methylbenzamide;

Methyl 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-1H-indazol-1-yl]sulfonylmethylbenzoate;

N-Cyclopropyl-3-[1-[(3,4-dimethoxyphenyl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-[1-[[4-(trifluoromethyl)phenyl]sulfonyl]-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-[1-[(4-fluorophenyl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide;

4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)-N-(1,3-thiazol-2-yl)benzamide;

N-Cyclopropyl-4-methyl-3-[3-(1-piperazinyl)-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[3-(4-morpholinyl)-1,2-benzisoxazol-6-yl]benzamide; (GW 847638X)

N-Cyclopropyl-4-methyl-3-[3-[2-oxo-2-(1-piperazinyl)ethyl]-1,2-benzisoxazol-6-yl]benzamide; (GW 838902X)

Methyl (6-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-1,2-benzisoxazol-3-yl)acetate;

N-Cyclopropyl-3-(3-[2-[(2-hydroxyethyl)amino]-2-oxoethyl]-1,2-benzisoxazol-6-yl)-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-[3-[2-oxo-2-(1-piperidinyl)ethyl]-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[3-[2-(methylamino)-2-oxoethyl]-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-3-(3-[2-[(3-hydroxypropyl)amino]-2-oxoethyl]-1,2-benzisoxazol-6-yl)-4-methylbenzamide;

N-Cyclopropyl-3-(3-[2-[(cyclopropylmethyl)amino]-2-oxoethyl]-1,2-benzisoxazol-6-yl)-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-[3-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-3-[3-[2-(ethylamino)-2-oxoethyl]-1,2-benzisoxazol-6-yl]-4-methylbenzamide;

N-Cyclopropyl-3-[3-[2-(cyclopropylamino)-2-oxoethyl]-1,2-benzisoxazol-6-yl]-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-[3-[2-(4-morpholinyl)-2-oxoethyl]-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[3-[2-({[3-(methyloxy)phenyl]methyl}amino)-2-oxoethyl]-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[3-[2-oxo-2-(1,3-thiazol-2-ylamino)ethyl]-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[3-[(4-methyl-1-piperazinyl)methyl]-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[3-(1-piperidinylmethyl)-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[3-(4-morpholinylmethyl)-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[3-(1-pyrrolidinylmethyl)-1,2-benzisoxazol-6-yl]benzamide;

3-(3-Amino-1,2-benzisoxazol-6-yl)-N-cyclopropyl-4-methylbenzamide;

N-Cyclopropyl-3-[3-(cyclopropylamino)-1,2-benzisoxazol-6-yl]-5-fluoro-4-methylbenzamide;

6-[5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-(cyclopropylmethyl)-1,2-benzisoxazole-3-carboxamide;

6-[5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-propyl-1,2-benzisoxazole-3-carboxamide;

6-[5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-methyl-1,2-benzisoxazole-3-carboxamide;

6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N,N-dimethyl-1,2-benzisoxazole-3-carboxamide;

N-Cyclopropyl-6-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-1,2-benzisoxazole-3-carboxamide;

1,1-Dimethylethyl 5-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-1H-indazole-1-carboxylate;

N-Cyclopropyl-3-fluoro-5-(1H-indazol-5-yl)-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-{1-[(1-methylethyl)sulfonyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-3-[1-(ethylsulfonyl)-1H-indazol-5-yl]-4-methylbenzamide;

N-Cyclopropyl-3-[1-(cyclopropylsulfonyl)-1H-indazol-5-yl]-4-methylbenzamide;

Methyl 5-[(5-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-1H-indazol-1-yl)sulfonyl]-2-furancarboxylate;

3-[1-(2,1,3-Benzoxadiazol-4-ylsulfonyl)-1H-indazol-5-yl]-N-cyclopropyl-4-methylbenzamide;

N-Cyclopropyl-3-{1-[(2-fluorophenyl)sulfonyl]-1H-indazol-5-yl}-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-{1-[(4-methylphenyl)sulfonyl]-1H-indazol-5-yl}benzamide;  
(GW-850903X)

N-Cyclopropyl-4-methyl-3-[1-(2-thienylsulfonyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-{1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-1H-indazol-5-yl}-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-[1-(propylsulfonyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-4-methyl-3-{1-[(2-nitrophenyl)sulfonyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-4-methyl-3-{1-[(2,2,2-trifluoroethyl)sulfonyl]-1H-indazol-5-yl}benzamide;

3-[1-[(2-Cyanophenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-[1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(2-thienylsulfonyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(3-thienylsulfonyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(4-methylphenyl)sulfonyl]-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-(1-[[4-(methyloxy)phenyl]sulfonyl]-1H-indazol-5-yl)benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-(1-[[4-(1-methylethyl)phenyl]sulfonyl]-1H-indazol-5-yl)benzamide;

3-[1-[(4-Chlorophenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-[1-[(2,4-difluorophenyl)sulfonyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide;

3-[1-[(3-Chlorophenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-5-[1-[(5-fluoro-2-methylphenyl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-5-[1-[(3-fluorophenyl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-(1-[[3-(methyloxy)phenyl]sulfonyl]-1H-indazol-5-yl)benzamide;



N-Cyclopropyl-3-[1-[(3,5-difluorophenyl)sulfonyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(3-methylphenyl)sulfonyl]-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(1-methylethyl)sulfonyl]-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(propylsulfonyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(methylsulfonyl)-1H-indazol-5-yl]benzamide;

3-[1-(Butylsulfonyl)-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(octylsulfonyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-[1-(cyclopropylsulfonyl)-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide;

3-[1-[(5-Chloro-2-thienyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-[1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-[1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-[1-(ethylsulfonyl)-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide;

3-[1-[(2-Chlorophenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(2-methylphenyl)sulfonyl]-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-[1-[(4-ethylphenyl)sulfonyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(4-propylphenyl)sulfonyl]-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-[1-[(3,4-difluorophenyl)sulfonyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide;

3-[1-[(4-Butylphenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(phenylsulfonyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(phenylmethyl)sulfonyl]-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-(1-[(E)-2-phenylethenyl]sulfonyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-[1-[(2,5-difluorophenyl)sulfonyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-5-[1-[(2-fluorophenyl)sulfonyl]-1H-indazol-5-yl]-4-methylbenzamide;

3-[1-[(4-Cyanophenyl)sulfonyl]-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-[1-(2,3-dihydro-1-benzofuran-5-ylsulfonyl)-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(4-methylphenyl)sulfonyl]-1H-indol-5-yl]benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(phenylsulfonyl)-1H-indol-5-yl]benzamide;

N-Cyclopropyl-3-[1-(cyclopropylmethyl)-1H-indazol-5-yl]-4-methylbenzamide;

1,1-Dimethylethyl 4-(5-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-1H-indazol-1-yl)-1-piperidinecarboxylate;

N-Cyclopropyl-4-methyl-3-[1-(4-piperidinyl)-1H-indazol-5-yl]benzamide hydrochloride;

Methyl-5-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-1H-indazol-1-yl]acetate;

N-Cyclopropyl-3-(1H-indazol-6-yl)-4-methylbenzamide;

N-Cyclopropyl-3-[3-[(4-fluorophenyl)sulfonyl]-1H-indazol-6-yl]-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[3-(methylsulfonyl)-1H-indazol-6-yl]benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-(3-methyl-1H-indazol-5-yl)benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[3-methyl-1-(2-thienylsulfonyl)-1H-indazol-5-yl]benzamide; (GSK239043A)

Methyl-5-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-1H-indazol-1-yl]acetate; (GSK251057A)

N-Cyclopropyl-4-methyl-3-[1-[2-((4-(methoxy)phenyl)methyl)amino]-2-oxoethyl]-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[1-[2-oxo-2-[(phenylmethyl)amino]ethyl]-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[1-[2-[[4-(4-methylphenyl)methyl]amino]-2-oxoethyl]-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[1-[2-[[4-[(methylamino)carbonyl]phenyl)methyl]amino]-2-oxoethyl]-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[1-[2-oxo-2-(propylamino)ethyl]-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-[1-[2-[(cyclopropylmethyl)amino]-2-oxoethyl]-1H-indazol-5-yl]-4-methylbenzamide;

N-Cyclopropyl-3-[1-[2-[(2,2-dimethylpropyl)amino]-2-oxoethyl]-1H-indazol-5-yl]-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-{1-[2-(4-morpholinyl)-2-oxoethyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-{1-[2-oxo-2-[(phenylmethyl)amino]ethyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(2-[[[(4-methylphenyl)methyl]amino]-2-oxoethyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-{1-[2-[[[4-(methyloxy)phenyl]methyl]amino]-2-oxoethyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-{1-[2-[[[(4-[(methylamino)carbonyl]phenyl)methyl]amino]-2-oxoethyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-{1-[2-oxo-2-(propylamino)ethyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-3-{1-[2-[(cyclopropylmethyl)amino]-2-oxoethyl]-1H-indazol-5-yl}-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-{1-[2-(4-morpholinyl)-2-oxoethyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-4-methyl-3-{1-[2-[(1-methylethyl)amino]-2-oxoethyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-3-{1-[2-[(2,2-dimethylpropyl)amino]-2-oxoethyl]-1H-indazol-5-yl}-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-{2-[(cyclopropylcarbonyl)amino]-1,3-benzothiazol-6-yl}-4-methylbenzamide; or a pharmaceutically acceptable salt thereof.


7 (previously presented). A pharmaceutical composition comprising a compound according to claim 1 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

8 (previously presented). A method for treating a condition or disease state mediated by p38 kinase activity in a patient in need thereof comprising administering to said patient a compound according to claim 1.

9 (previously presented). A method for treating mediated by cytokines produced by the activity of p38 kinase in a patient in need thereof, comprising administering to said patient an effective amount of a compound according to claim 1.


10 (previously presented). A process for preparing a compound of formula (I) according to claim 1 which comprises

(a) reacting a compound of formula (II)




(II)

in which A is defined in claim 1 and Z<sup>1</sup> is halogen,  
with a compound of formula (IIIA) or (IIIB)



(IIIA)




(IIIB)

in which R<sup>1</sup>, R<sup>2</sup>, X and Y are as defined in claim 1,  
in the presence of a catalyst, or

(b) final stage modification of one compound of formula (I) as defined in claim 1 to give another compound of formula (I) as defined in claim 1.

11 (original). A compound of formula (IA):



(IA)

wherein

A is a fused 5-membered heteroaryl ring optionally substituted by up to two substituents independently selected from C<sub>1-6</sub>alkyl, -(CH<sub>2</sub>)<sub>m</sub>-C<sub>3-7</sub>cycloalkyl, halogen, cyano, trifluoromethyl, -(CH<sub>2</sub>)<sub>m</sub>OR<sup>3</sup>, -(CH<sub>2</sub>)<sub>m</sub>NR<sup>3</sup>R<sup>4</sup>, -(CH<sub>2</sub>)<sub>m</sub>CONR<sup>3</sup>R<sup>4</sup>, -(CH<sub>2</sub>)<sub>m</sub>NHCOR<sup>3</sup>, -(CH<sub>2</sub>)<sub>m</sub>SO<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>, -(CH<sub>2</sub>)<sub>m</sub>NHSO<sub>2</sub>R<sup>3</sup>, -(CH<sub>2</sub>)<sub>m</sub>SO<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>R<sup>5</sup>, a 5- or 6-membered heterocyclyl ring containing nitrogen optionally substituted by C<sub>1-2</sub>alkyl and a 5-membered heteroaryl ring optionally substituted by C<sub>1-2</sub>alkyl;

R<sup>1</sup> is selected from methyl and chloro;

R<sup>2</sup> is selected from -NH-CO-R<sup>6</sup> and -CO-NH-(CH<sub>2</sub>)<sub>q</sub>-R<sup>7</sup>;

R<sup>3</sup> is selected from hydrogen, C<sub>1-6</sub>alkyl optionally substituted by up to two OH groups, -(CH<sub>2</sub>)<sub>m</sub>-C<sub>3-7</sub>cycloalkyl, -(CH<sub>2</sub>)<sub>m</sub>phenyl optionally substituted by R<sup>8</sup> and/or R<sup>9</sup> and -(CH<sub>2</sub>)<sub>m</sub>heteroaryl optionally substituted by R<sup>8</sup> and/or R<sup>9</sup>

R<sup>4</sup> is selected from hydrogen and C<sub>1-6</sub>alkyl, or

R<sup>3</sup> and R<sup>4</sup>, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R<sup>10</sup>;

R<sup>5</sup> is selected from C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, heteroaryl optionally substituted by R<sup>8</sup> and/or R<sup>9</sup>, and phenyl optionally substituted by R<sup>8</sup> and/or R<sup>9</sup>;

R<sup>6</sup> is selected from hydrogen, C<sub>1-6</sub>alkyl, -(CH<sub>2</sub>)<sub>q</sub>-C<sub>3-7</sub>cycloalkyl, trifluoromethyl, -(CH<sub>2</sub>)<sub>r</sub>-heteroaryl optionally substituted by R<sup>11</sup> and/or R<sup>12</sup>, and -(CH<sub>2</sub>)<sub>r</sub>-phenyl optionally substituted by R<sup>11</sup> and/or R<sup>12</sup>;

R<sup>7</sup> is selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, CONHR<sup>13</sup>, phenyl optionally substituted by R<sup>11</sup> and/or R<sup>12</sup>, and heteroaryl optionally substituted by R<sup>11</sup> and/or R<sup>12</sup>;

R<sup>8</sup> and R<sup>9</sup> are each independently selected from halogen, cyano, trifluoromethyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, COR<sup>15</sup>, CO<sub>2</sub>R<sup>15</sup>, and heteroaryl, or

R<sup>8</sup> and R<sup>9</sup> are linked to form a fused 5-membered heterocyclyl ring containing one heteroatom selected from oxygen, sulphur and N-R<sup>10</sup>;

R<sup>10</sup> is selected from hydrogen and methyl;

R<sup>11</sup> is selected from C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, -(CH<sub>2</sub>)<sub>q</sub>-C<sub>3-7</sub>cycloalkyl, -CONR<sup>13</sup>R<sup>14</sup>, -NHCOR<sup>14</sup>, halogen, CN, -(CH<sub>2</sub>)<sub>s</sub>NR<sup>16</sup>R<sup>17</sup>, trifluoromethyl, phenyl optionally substituted by one or more R<sup>12</sup> groups, and heteroaryl optionally substituted by one or more R<sup>12</sup> groups;

R<sup>12</sup> is selected from C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, trifluoromethyl, and -(CH<sub>2</sub>)<sub>s</sub>NR<sup>16</sup>R<sup>17</sup>;

R<sup>13</sup> and R<sup>14</sup> are each independently selected from hydrogen and C<sub>1-6</sub>alkyl, or

R<sup>13</sup> and R<sup>14</sup>, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R<sup>10</sup>, wherein the ring may be substituted by up to two C<sub>1-6</sub>alkyl groups;

R<sup>15</sup> is C<sub>1-6</sub>alkyl;

R<sup>16</sup> is selected from hydrogen, C<sub>1-6</sub>alkyl and -(CH<sub>2</sub>)<sub>q</sub>-C<sub>3-7</sub>cycloalkyl optionally substituted by C<sub>1-6</sub>alkyl,

R<sup>17</sup> is selected from hydrogen and C<sub>1-6</sub>alkyl, or

R<sup>16</sup> and R<sup>17</sup>, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R<sup>10</sup>;

m is selected from 0, 1, 2 and 3;

n is selected from 0, 1, 2 and 3;

q is selected from 0, 1 and 2;

r is selected from 0 and 1; and

s is selected from 0, 1, 2 and 3.

12 (currently amended). A compound according to claim 1 which is:

N-[4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide;

N-cyclopropyl-4-methyl-3-[1-(phenylsulfonyl)-1H-indazol-5-yl]benzamide;

N-cyclopropyl-3-{1-[(3-fluorophenyl)sulfonyl]-1H-indazol-5-yl}-4-methylbenzamide;

N-cyclopropyl-4-methyl-3-[1-(methylsulfonyl)-1H-indazol-5-yl]benzamide;

N-cyclopropyl-3-{1-[(4-fluorophenyl)sulfonyl]-1H-indazol-5-yl}-4-methyl benzamide;

N -cyclopropyl-4-methyl-3-[3-(4-morpholinyl)-1,2-benzisoxazol-6-yl]benzamide;

N-cyclopropyl-4-methyl-3-{3-[2-oxo-2-(1,3-thiazol-2-ylamino)ethyl]-1,2-benzisoxazol-6-yl} benzamide;

N-cyclopropyl-4-methyl-3-[3-(4-morpholinylmethyl)-1,2-benzisoxazol-6-yl]benzamide;

N-cyclopropyl-4-methyl-3-[3-(1-pyrrolidinylmethyl)-1,2-benzisoxazol-6-yl]benzamide;

N-cyclopropyl-4-methyl-3-{1-[(1-methylethyl)sulfonyl]-1H-indazol-5-yl} benzamide);

N-cyclopropyl-3-[1-(ethylsulfonyl)-1H-indazol-5-yl]-4-methylbenzamide;

N-cyclopropyl-3-[1-(cyclopropylsulfonyl)-1H-indazol-5-yl]-4-methylbenzamide;

N-cyclopropyl-4-methyl-3-[1-(2-thienylsulfonyl)-1H-indazol-5-yl]benzamide;

3-{1-[(2-cyanophenyl)sulfonyl]-1H-indazol-5-yl}-N-cyclopropyl-4-methylbenzamide;

N-cyclopropyl-3-fluoro-4-methyl-5-[1-(2-thienylsulfonyl)-1H-indazol-5-yl]benzamide;

N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-thienylsulfonyl)-1H-indazol-5-yl]benzamide;

N-cyclopropyl-3-fluoro-4-methyl-5-{1-[(1-methylethyl)sulfonyl]-1H-indazol-5-yl} benzamide;

N-cyclopropyl-3-fluoro-4-methyl-5-[1-(propylsulfonyl)-1H-indazol-5-yl]benzamide;

N-cyclopropyl-3-fluoro-4-methyl-5-[1-(methylsulfonyl)-1H-indazol-5-yl]benzamide;



3-[1-(butylsulfonyl)-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide;

N-cyclopropyl-3-[1-(cyclopropylsulfonyl)-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide;

3-{1-[(5-chloro-2-thienyl)sulfonyl]-1H-indazol-5-yl}-N-cyclopropyl-5-fluoro-4-methylbenzamide;

N-cyclopropyl-3-{1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-1H-indazol-5-yl}-5-fluoro-4-methylbenzamide;

N-cyclopropyl-3-[1-(ethylsulfonyl)-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide;

3-{1-[(2-chlorophenyl)sulfonyl]-1H-indazol-5-yl}-N-cyclopropyl-5-fluoro-4-methylbenzamide;

N-cyclopropyl-3-fluoro-4-methyl-5-{1-[(2-methylphenyl)sulfonyl]-1H-indazol-5-yl}benzamide;

N-cyclopropyl-3-fluoro-4-methyl-5-[1-(phenylsulfonyl)-1H-indazol-5-yl]benzamide;

N-cyclopropyl-3-{1-[(2,5-difluorophenyl)sulfonyl]-1H-indazol-5-yl}-5-fluoro-4-methylbenzamide;

N-cyclopropyl-3-fluoro-5-{1-[(2-fluorophenyl)sulfonyl]-1H-indazol-5-yl}-4-methylbenzamide;

N-cyclopropyl-3-[1-(cyclopropylmethyl)-1H-indazol-5-yl]-4-methylbenzamide;  
[[and ]] or

N-cyclopropyl-3-fluoro-4-methyl-5-[3-methyl-1-(2-thienylsulfonyl)-1H-indazol-5-yl]benzamide; or a pharmaceutically acceptable salt thereof.

13. (new) A method for treating a condition or disease state mediated by p38 kinase activity according to Claim 8 wherein the disease or condition is in a human and the disease or condition is selected from the group consisting of rheumatoid arthritis, asthma, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, and neurodegenerative disease.

14. (new) A method for treating a condition or disease state mediated by p38 kinase activity according to Claim 8 wherein the disease or condition is in a human and the disease or condition is selected from the group consisting of chronic pain, neuromuscular pain, headache, cancer pain, acute and chronic inflammatory pain associated with osteoarthritis and rheumatoid arthritis, post operative inflammatory pain, neuropathic pain, diabetic neuropathy, trigeminal neuralgia, post-hepatic neuralgia, inflammatory neuropathies and migraine pain.

15. (new). A compound according to claim 1 which is:

N-[4-Methyl-3-(3-methyl-1,2-benzisoxazol-5-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide;

N-Cyclopropyl-3-[3-({[2-hydroxy-1-(hydroxymethyl)ethyl]amino} methyl)-1,2-benzisoxazol-6-yl]-4-methylbenzamide;

N-(3-Methoxyphenyl)-4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)benzamide;

4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)-N-(1,3,4-thiadiazol-2-yl)benzamide;

N-[4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]thiophene-3-carboxamide;

N-[4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]-3-furamide;

N-(Cyclopropylmethyl)-4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)benzamide;

or a pharmaceutically acceptable salt thereof.

16. (new). A compound according to claim 1 which is:

N-Cyclopropyl-3-(1H-indazol-5-yl)-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-[1-(phenylsulfonyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-{1-[(3-fluorophenyl)sulfonyl]-1H-indazol-5-yl}-4-methylbenzamide

3-{1-[(3-Cyanophenyl)sulfonyl]-1H-indazol-5-yl}-N-cyclopropyl-4-methylbenzamide;

N-Cyclopropyl-3-{1-[(3,4-difluorophenyl)sulfonyl]-1H-indazol-5-yl}-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-[1-(methylsulfonyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-[1-(2,3-dihydro-1-benzofuran-5-ylsulfonyl)-1H-indazol-5-yl]-4-methylbenzamide;

N-Cyclopropyl-3-{1-[(3-methoxyphenyl)sulfonyl]-1H-indazol-5-yl}-4-methylbenzamide;

3-[1-(Benzylsulfonyl)-1H-indazol-5-yl]-N-cyclopropyl-4-methylbenzamide;

N-Cyclopropyl-3-{1-[(5-isoxazol-3-ylthien-2-yl)sulfonyl]-1H-indazol-5-yl}-4-methylbenzamide;

3-{1-[(4-Acetylphenyl)sulfonyl]-1H-indazol-5-yl}-N-cyclopropyl-4-methylbenzamide;

Methyl 4-{[(5-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-1H-indazol-1-yl)sulfonyl]methyl}benzoate;

N-Cyclopropyl-3-{1-[(3,4-dimethoxyphenyl)sulfonyl]-1H-indazol-5-yl}-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-(1-{[4-(trifluoromethyl)phenyl]sulfonyl}-1H-indazol-5-yl)benzamide;

N-Cyclopropyl-3-{1-[(4-fluorophenyl)sulfonyl]-1H-indazol-5-yl}-4-methylbenzamide; or a pharmaceutically acceptable salt thereof.

17. (new) A compound according to Claim 1 which is

4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)-N-(1,3-thiazol-2-yl)benzamide;

N-Cyclopropyl-4-methyl-3-[3-(1-piperazinyl)-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[3-(4-morpholinyl)-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-oxo-2-(1-piperazinyl)ethyl]-1,2-benzisoxazol-6-yl}benzamide;

Methyl (6-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-1,2-benzisoxazol-3-yl)acetate;

N-Cyclopropyl-3-(3-{2-[(2-hydroxyethyl)amino]-2-oxoethyl}-1,2-benzisoxazol-6-yl)-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-oxo-2-(1-piperidinyl)ethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-(methylamino)-2-oxoethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-3-(3-{2-[(3-hydroxypropyl)amino]-2-oxoethyl}-1,2-benzisoxazol-6-yl)-4-methylbenzamide;

N-Cyclopropyl-3-(3-{2-[(cyclopropylmethyl)amino]-2-oxoethyl}-1,2-benzisoxazol-6-yl)-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-3-{3-[2-(ethylamino)-2-oxoethyl]-1,2-benzisoxazol-6-yl}-4-methylbenzamide;

N-Cyclopropyl-3-{3-[2-(cyclopropylamino)-2-oxoethyl]-1,2-benzisoxazol-6-yl}-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-(4-morpholinyl)-2-oxoethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-({[3-(methyloxy)phenyl]methyl}amino)-2-oxoethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-oxo-2-(1,3-thiazol-2-ylamino)ethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-4-methyl-3-{3-[(4-methyl-1-piperazinyl)methyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-4-methyl-3-[3-(1-piperidinylmethyl)-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[3-(4-morpholinylmethyl)-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[3-(1-pyrrolidinylmethyl)-1,2-benzisoxazol-6-yl]benzamide;

3-(3-Amino-1,2-benzisoxazol-6-yl)-N-cyclopropyl-4-methylbenzamide;

N-Cyclopropyl-3-[3-(cyclopropylamino)-1,2-benzisoxazol-6-yl]-5-fluoro-4-methylbenzamide;

6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N-(cyclopropylmethyl)-1,2-benzisoxazole-3-carboxamide;

6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N-propyl-1,2-benzisoxazole-3-carboxamide;

6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N-methyl-1,2-benzisoxazole-3-carboxamide;

6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N,N-dimethyl-1,2-benzisoxazole-3-carboxamide;

N-Cyclopropyl-6-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-1,2-benzisoxazole-3-carboxamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-{1-[(4-methylphenyl)sulfonyl]-1H-indol-5-yl}benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(phenylsulfonyl)-1H-indol-5-yl]benzamide;

N-Cyclopropyl-3-{2-[(cyclopropylcarbonyl)amino]-1,3-benzothiazol-6-yl}-4-methylbenzamide; or a pharmaceutically acceptable salt thereof.

18.(new). The compound according to Claim 1 which is:

1,1-Dimethylethyl 5-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-1H-indazole-1-carboxylate;

N-Cyclopropyl-3-fluoro-5-(1H-indazol-5-yl)-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-{1-[(1-methylethyl)sulfonyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-3-[1-(ethylsulfonyl)-1H-indazol-5-yl]-4-methylbenzamide;

N-Cyclopropyl-3-[1-(cyclopropylsulfonyl)-1H-indazol-5-yl]-4-methylbenzamide;

Methyl 5-[(5-{[(cyclopropylamino)carbonyl]-2-methylphenyl}-1H-indazol-1-yl)sulfonyl]-2-furancarboxylate;

3-[1-(2,1,3-Benzoxadiazol-4-ylsulfonyl)-1H-indazol-5-yl]-N-cyclopropyl-4-methylbenzamide;

N-Cyclopropyl-3-{1-[(2-fluorophenyl)sulfonyl]-1H-indazol-5-yl}-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-{1-[(4-methylphenyl)sulfonyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-4-methyl-3-[1-(2-thienylsulfonyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-{1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-1H-indazol-5-yl}-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-[1-(propylsulfonyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-4-methyl-3-{1-[(2-nitrophenyl)sulfonyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-4-methyl-3-{1-[(2,2,2-trifluoroethyl)sulfonyl]-1H-indazol-5-yl}benzamide;

3-{1-[(2-Cyanophenyl)sulfonyl]-1H-indazol-5-yl}-N-cyclopropyl-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-{1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-4-methyl-3-{1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(2-thienylsulfonyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(3-thienylsulfonyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-{1-[(4-methylphenyl)sulfonyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-(1-{[4-(methyloxy)phenyl]sulfonyl}-1H-indazol-5-yl)benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-(1-{[4-(1-methylethyl)phenyl]sulfonyl}-1H-indazol-5-yl)benzamide;

3-{1-{[4-Chlorophenyl]sulfonyl}-1H-indazol-5-yl}-N-cyclopropyl-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-{1-{[2,4-difluorophenyl]sulfonyl}-1H-indazol-5-yl}-5-fluoro-4-methylbenzamide;

3-{1-{[3-Chlorophenyl]sulfonyl}-1H-indazol-5-yl}-N-cyclopropyl-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-5-{1-{[5-fluoro-2-methylphenyl]sulfonyl}-1H-indazol-5-yl}-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-5-{1-{[3-fluorophenyl]sulfonyl}-1H-indazol-5-yl}-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-(1-{[3-(methyloxy)phenyl]sulfonyl}-1H-indazol-5-yl)benzamide;

N-Cyclopropyl-3-{1-{[3,5-difluorophenyl]sulfonyl}-1H-indazol-5-yl}-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-{1-{[3-methylphenyl]sulfonyl}-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-{1-{[1-methylethyl]sulfonyl}-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(propylsulfonyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(methylsulfonyl)-1H-indazol-5-yl]benzamide;

3-[1-(Butylsulfonyl)-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(octylsulfonyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-[1-(cyclopropylsulfonyl)-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide;

3-{1-[(5-Chloro-2-thienyl)sulfonyl]-1H-indazol-5-yl}-N-cyclopropyl-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-{1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-1H-indazol-5-yl}-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-{1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-1H-indazol-5-yl}-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-[1-(ethylsulfonyl)-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide;

3-{1-[(2-Chlorophenyl)sulfonyl]-1H-indazol-5-yl}-N-cyclopropyl-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-{1-[(2-methylphenyl)sulfonyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-3-{1-[(4-ethylphenyl)sulfonyl]-1H-indazol-5-yl}-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-{1-[(4-propylphenyl)sulfonyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-3-{1-[(3,4-difluorophenyl)sulfonyl]-1H-indazol-5-yl}-5-fluoro-4-methylbenzamide;

3-{1-[(4-Butylphenyl)sulfonyl]-1H-indazol-5-yl}-N-cyclopropyl-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(phenylsulfonyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-{1-[(phenylmethyl)sulfonyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-(1-[[E]-2-phenylethenyl]sulfonyl)-1H-indazol-5-yl)benzamide;



N-Cyclopropyl-3-{1-[(2,5-difluorophenyl)sulfonyl]-1H-indazol-5-yl}-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-5-{1-[(2-fluorophenyl)sulfonyl]-1H-indazol-5-yl}-4-methylbenzamide;

3-{1-[(4-Cyanophenyl)sulfonyl]-1H-indazol-5-yl}-N-cyclopropyl-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-[1-(2,3-dihydro-1-benzofuran-5-ylsulfonyl)-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide; or a pharmaceutically acceptable salt thereof.

19. (new) The compound according to Claim 1 which is;

N-Cyclopropyl-3-[1-(cyclopropylmethyl)-1H-indazol-5-yl]-4-methylbenzamide;

1,1-Dimethylethyl 4-(5-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-1H-indazol-1-yl)-1-piperidinecarboxylate;

N-Cyclopropyl-4-methyl-3-[1-(4-piperidiny)-1H-indazol-5-yl]benzamide hydrochloride;

Methyl (5-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-1H-indazol-1-yl)acetate;

N-Cyclopropyl-3-(1H-indazol-6-yl)-4-methylbenzamide;

N-Cyclopropyl-3-{3-[(4-fluorophenyl)sulfonyl]-1H-indazol-6-yl}-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[3-(methylsulfonyl)-1H-indazol-6-yl]benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-(3-methyl-1H-indazol-5-yl)benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[3-methyl-1-(2-thienylsulfonyl)-1H-indazol-5-yl]benzamide;

Methyl (5-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-1H-indazol-1-yl)acetate;

N-Cyclopropyl-4-methyl-3-{1-[2-({[4-(methyloxy)phenyl]methyl}amino)-2-oxoethyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-4-methyl-3-(1-{2-oxo-2-[(phenylmethyl)amino]ethyl}-1H-indazol-5-yl)benzamide;

N-Cyclopropyl-4-methyl-3-[1-(2-{[(4-methylphenyl)methyl]amino}-2-oxoethyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-4-methyl-3-(1-{2-[(4-[(methylamino)carbonyl]phenyl)methyl]amino}-2-oxoethyl)-1H-indazol-5-yl)benzamide;

N-Cyclopropyl-4-methyl-3-{1-[2-oxo-2-(propylamino)ethyl]-1H-indazol-5-yl} benzamide;

N-Cyclopropyl-3-(1-{2-[(cyclopropylmethyl)amino]-2-oxoethyl}-1H-indazol-5-yl)-4-methylbenzamide;

N-Cyclopropyl-3-(1-{2-[(2,2-dimethylpropyl)amino]-2-oxoethyl}-1H-indazol-5-yl)-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-{1-[2-(4-morpholinyl)-2-oxoethyl]-1H-indazol-5-yl} benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-(1-{2-oxo-2-[(phenylmethyl)amino]ethyl}-1H-indazol-5-yl)benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(2-{[(4-methylphenyl)methyl]amino}-2-oxoethyl)-1H-indazol-5-yl]benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-{1-[2-({[4-(methyloxy)phenyl]methyl}amino)-2-oxoethyl]-1H-indazol-5-yl} benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-(1-{2-[(4-[(methylamino)carbonyl]phenyl)methyl]amino}-2-oxoethyl)-1H-indazol-5-yl)benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-{1-[2-oxo-2-(propylamino)ethyl]-1H-indazol-5-yl} benzamide;

N-Cyclopropyl-3-(1-{2-[(cyclopropylmethyl)amino]-2-oxoethyl}-1H-indazol-5-yl)-5-fluoro-4-methylbenzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-{1-[2-(4-morpholinyl)-2-oxoethyl]-1H-indazol-5-yl}benzamide;

N-Cyclopropyl-4-methyl-3-(1-{2-[(1-methylethyl)amino]-2-oxoethyl}-1H-indazol-5-yl)benzamide;

N-Cyclopropyl-3-(1-{2-[(2,2-dimethylpropyl)amino]-2-oxoethyl}-1H-indazol-5-yl)-5-fluoro-4-methylbenzamide;

or a pharmaceutically acceptable salt thereof.

20. (new) A pharmaceutical composition comprising a compound according to claim 6 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

21. (new) A pharmaceutical composition comprising a compound according to claim 12 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

22. (new) A pharmaceutical composition comprising a compound according to claim 15 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

23. (new) A pharmaceutical composition comprising a compound according to claim 16 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

24. (new) A pharmaceutical composition comprising a compound according to claim 17 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

25. (new) A pharmaceutical composition comprising a compound according to claim 18 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

26. (new) A pharmaceutical composition comprising a compound according to claim 19 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.